Core Insights - Dingtang Health has launched the innovative drug Lishengqizhu Injection (brand name: Xika Yue) in its DTP pharmacies, expanding treatment options for eligible patients [1] - The innovative drug market is projected to become a significant growth engine for the pharmaceutical industry, with East Wu Securities forecasting a market size exceeding 2 trillion yuan by 2030, representing a compound annual growth rate of 24.1% [1] - Dingtang Health is actively implementing initiatives such as the "New Specialty Drug · Life Ark" plan and the "Original Drug Supply Alliance," introducing numerous innovative drugs across various fields, thereby improving medication accessibility and adherence for patients [1] Company Strategy - The company is enhancing its supply chain and digital service capabilities, establishing intelligent warehouses in North, Central, East, and South China, and developing cold chain delivery services in major cities [1] - Dingtang Health has integrated "instant drug retail + health education + digital services" into a comprehensive management model, facilitating disease education, online consultations, and regular follow-up services for patients [1] - Industry experts believe that Dingtang Health's focus on innovative drugs positions it as a pivotal link in the outpatient market for innovative pharmaceuticals, positively impacting the development of the pharmaceutical retail sector [2]